Mouse CD40L ELISA Kit (ab119517)
Key features and details
- Sensitivity: 0.14 ng/ml
- Range: 0.31 ng/ml - 20 ng/ml
- Sample type: Cell culture supernatant, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Mouse
製品の概要
-
製品名
Mouse CD40L ELISA Kit
TRAP/CD40L キット 製品一覧 -
検出方法
Colorimetric -
再現性
Intra-Assay(同時再現性) サンプル N 平均値 SD CV% Overall 8 6.5% Inter-Assay(日差再現性) サンプル N 平均値 SD CV% Overall 8 11.1% -
サンプルの種類
Cell culture supernatant, Serum -
アッセイタイプ
Sandwich (quantitative) -
検出感度
0.14 ng/ml -
検出範囲
0.31 ng/ml - 20 ng/ml -
添加回収試験
94 %
-
ステップ
Multiple steps standard assay -
種交差性
交差種: Mouse -
製品の概要
Abcam’s CD40L Mouse in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for accurate quantitative measurement of Mouse CD40L concentrations in cell culture supernatant and serum.
CD40L specific antibodies have been precoated onto 96-well plates. Standards and test samples are added to the wells along with a biotin-conjugated CD40L detection antibody then incubated at room temperature. Following washing, a Streptavidin-HRP conjugate is added to each well, incubated at room temperature and washed. TMB is added and then catalyzed by HRP to produce a blue product that changes to yellow after the addition of acidic stop solution. The density of yellow coloration is directly proportional to the amount of CD40L captured on the plate.
-
試験プラットフォーム
Microplate
製品の特性
-
保存方法
Store at +4°C. Please refer to protocols. -
内容 1 x 96 tests 20X Assay Buffer Concentrate 1 x 5ml 20X Wash Buffer Concentrate 1 x 50ml Adhesive Films 4 units Biotin-Conjugate anti-mouse CD40L monoclonal antibody 1 x 70µl Microplate coated with monoclonal antibody to mouse CD40L (12 x 8 wells) 1 unit Mouse CD40L Standard lyophilized (40 ng /mL upon reconstitution) 2 vials Sample Diluent 1 x 12ml Stop Solution (1M Phosphoric acid) 1 x 15ml Streptavidin-HRP 1 x 150µl TMB Substrate Solution 1 x 15ml -
研究分野
-
機能
Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.
Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway. -
組織特異性
Specifically expressed on activated CD4+ T-lymphocytes. -
関連疾患
Defects in CD40LG are the cause of X-linked immunodeficiency with hyper-IgM type 1 (HIGM1) [MIM:308230]; also known as X-linked hyper IgM syndrome (XHIM). HIGM1 is an immunoglobulin isotype switch defect characterized by elevated concentrations of serum IgM and decreased amounts of all other isotypes. Affected males present at an early age (usually within the first year of life) recurrent bacterial and opportunistic infections, including Pneumocystis carinii pneumonia and intractable diarrhea due to cryptosporidium infection. Despite substitution treatment with intravenous immunoglobulin, the overall prognosis is rather poor, with a death rate of about 10% before adolescence. -
配列類似性
Belongs to the tumor necrosis factor family. -
翻訳後修飾
The soluble form derives from the membrane form by proteolytic processing.
N-linked glycan is a mixture of high mannose and complex type. Glycan structure does not influence binding affinity to CD40.
Not O-glycosylated. -
細胞内局在
Secreted and Cell membrane. - Information by UniProt
-
別名
- CD 40L
- CD154
- CD40 antigen ligand
see all -
参照データベース
- Entrez Gene: 21947 Mouse
- SwissProt: P27548 Mouse
- Unigene: 4861 Mouse
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (4)
ab119517 は 4 報の論文で使用されています。
- Fihurka O et al. The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC. Int J Mol Sci 23:N/A (2022). PubMed: 35457070
- Lacy M et al. Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease. Nat Commun 12:3754 (2021). PubMed: 34145241
- Pototskiy E et al. Downregulation of CD40L-CD40 attenuates seizure susceptibility and severity of seizures. Sci Rep 11:17262 (2021). PubMed: 34446808
- Thomas S et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer 7:214 (2019). PubMed: 31399043